Bronchopulmonary Dysplasia - Pipeline Insight, 2025
Description
DelveInsight’s, “Bronchopulmonary Dysplasia - Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Bronchopulmonary Dysplasia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Bronchopulmonary Dysplasia: Overview
Bronchopulmonary dysplasia (BPD) is a serious lung condition primarily affecting premature infants, particularly those born before 32 weeks of gestation or with low birth weight. It is characterized by abnormal lung development and inflammation, often a result of prolonged oxygen therapy or mechanical ventilation required to support immature lungs. Infants with BPD experience difficulty breathing and may require long-term respiratory support, increasing their risk for further respiratory complications. The signs and symptoms of bronchopulmonary dysplasia (BPD) typically emerge in premature infants who require oxygen therapy or mechanical ventilation. Common symptoms include rapid or labored breathing (tachypnea), persistent need for supplemental oxygen, wheezing, and difficulty feeding. These infants may also show signs of poor growth and have episodes of cyanosis, where the skin appears bluish due to low oxygen levels. In severe cases, infants with BPD may develop chronic lung disease, experiencing frequent respiratory infections and needing long-term respiratory support.
The diagnosis of bronchopulmonary dysplasia (BPD) is typically made in premature infants who continue to require oxygen therapy or respiratory support after 28 days of life, especially if they are born before 32 weeks of gestation. BPD is confirmed based on clinical criteria, including the infant's oxygen dependence and radiographic evidence of lung abnormalities, such as hyperinflation, atelectasis, or fibrosis visible on chest X-rays. Physicians also assess the severity of BPD by evaluating the need for supplemental oxygen at 36 weeks postmenstrual age.
The treatment of bronchopulmonary dysplasia (BPD) focuses on managing symptoms and supporting lung development in affected infants. Key treatments include prolonged oxygen therapy or mechanical ventilation to maintain adequate oxygen levels, along with diuretics to reduce fluid buildup in the lungs and corticosteroids to minimize inflammation. Nutritional support is also crucial for promoting lung growth and overall development, while medications like bronchodilators can help open airways and improve breathing.
""Bronchopulmonary Dysplasia- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Bronchopulmonary Dysplasia pipeline landscape is provided which includes the disease overview and Bronchopulmonary Dysplasia treatment guidelines. The assessment part of the report embraces, in depth Bronchopulmonary Dysplasia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Bronchopulmonary Dysplasia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Bronchopulmonary Dysplasia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Bronchopulmonary Dysplasia Emerging Drugs
Further product details are provided in the report……..
Bronchopulmonary Dysplasia: Therapeutic Assessment
This segment of the report provides insights about the different Bronchopulmonary Dysplasia drugs segregated based on following parameters that define the scope of the report, such as:
Bronchopulmonary Dysplasia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Bronchopulmonary Dysplasia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bronchopulmonary Dysplasia drugs.
Bronchopulmonary Dysplasia Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Bronchopulmonary Dysplasia: Overview
Bronchopulmonary dysplasia (BPD) is a serious lung condition primarily affecting premature infants, particularly those born before 32 weeks of gestation or with low birth weight. It is characterized by abnormal lung development and inflammation, often a result of prolonged oxygen therapy or mechanical ventilation required to support immature lungs. Infants with BPD experience difficulty breathing and may require long-term respiratory support, increasing their risk for further respiratory complications. The signs and symptoms of bronchopulmonary dysplasia (BPD) typically emerge in premature infants who require oxygen therapy or mechanical ventilation. Common symptoms include rapid or labored breathing (tachypnea), persistent need for supplemental oxygen, wheezing, and difficulty feeding. These infants may also show signs of poor growth and have episodes of cyanosis, where the skin appears bluish due to low oxygen levels. In severe cases, infants with BPD may develop chronic lung disease, experiencing frequent respiratory infections and needing long-term respiratory support.
The diagnosis of bronchopulmonary dysplasia (BPD) is typically made in premature infants who continue to require oxygen therapy or respiratory support after 28 days of life, especially if they are born before 32 weeks of gestation. BPD is confirmed based on clinical criteria, including the infant's oxygen dependence and radiographic evidence of lung abnormalities, such as hyperinflation, atelectasis, or fibrosis visible on chest X-rays. Physicians also assess the severity of BPD by evaluating the need for supplemental oxygen at 36 weeks postmenstrual age.
The treatment of bronchopulmonary dysplasia (BPD) focuses on managing symptoms and supporting lung development in affected infants. Key treatments include prolonged oxygen therapy or mechanical ventilation to maintain adequate oxygen levels, along with diuretics to reduce fluid buildup in the lungs and corticosteroids to minimize inflammation. Nutritional support is also crucial for promoting lung growth and overall development, while medications like bronchodilators can help open airways and improve breathing.
""Bronchopulmonary Dysplasia- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Bronchopulmonary Dysplasia pipeline landscape is provided which includes the disease overview and Bronchopulmonary Dysplasia treatment guidelines. The assessment part of the report embraces, in depth Bronchopulmonary Dysplasia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Bronchopulmonary Dysplasia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Bronchopulmonary Dysplasia R&D. The therapies under development are focused on novel approaches to treat/improve Bronchopulmonary Dysplasia.
This segment of the Bronchopulmonary Dysplasia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Bronchopulmonary Dysplasia Emerging Drugs
- OHB-607: Oak Hill Bio
- AT-100: Airway Therapeutics, Inc
Further product details are provided in the report……..
Bronchopulmonary Dysplasia: Therapeutic Assessment
This segment of the report provides insights about the different Bronchopulmonary Dysplasia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Bronchopulmonary Dysplasia
- There are approx. 10+ key companies which are developing the therapies for Bronchopulmonary Dysplasia. The companies which have their Bronchopulmonary Dysplasia drug candidates in the most advanced stage, i.e. Phase II include, Oak Hill Bio and Medipost Co., Ltd.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Bronchopulmonary Dysplasia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Bronchopulmonary Dysplasia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bronchopulmonary Dysplasia drugs.
Bronchopulmonary Dysplasia Report Insights
- Bronchopulmonary Dysplasia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Bronchopulmonary Dysplasia drugs?
- How many Bronchopulmonary Dysplasia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Bronchopulmonary Dysplasia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Bronchopulmonary Dysplasia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Bronchopulmonary Dysplasia and their status?
- What are the key designations that have been granted to the emerging drugs?
- Medipost Co., Ltd.
- Oak Hill Bio
- EXO Biologics S.A.
- Airway Therapeutics, Inc
- Pneumostem
- OHB-607
- Endotracheopulmonary instillation
- AT-100
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Bronchopulmonary Dysplasia: Overview
- Introduction
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Bronchopulmonary Dysplasia– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- OHB-607: Oak Hill Bio
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- AT-100: Airway Therapeutics, Inc
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Bronchopulmonary Dysplasia Key Companies
- Bronchopulmonary Dysplasia Key Products
- Bronchopulmonary Dysplasia- Unmet Needs
- Bronchopulmonary Dysplasia- Market Drivers and Barriers
- Bronchopulmonary Dysplasia- Future Perspectives and Conclusion
- Bronchopulmonary Dysplasia Analyst Views
- Bronchopulmonary Dysplasia Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
